Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Change in Receivables (2016 - 2025)

Traws Pharma (TRAW) has disclosed Change in Receivables for 12 consecutive years, with $668000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables changed N/A to $668000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$130000.0, a N/A change, with the full-year FY2024 number at $1.7 million, up 15981.82% from a year prior.
  • Change in Receivables was $668000.0 for Q3 2025 at Traws Pharma, up from -$331000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $668000.0 in Q3 2025 to a low of -$356000.0 in Q4 2024.
  • A 5-year average of -$13727.3 and a median of -$1000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 101.89% in 2021, then plummeted 1100.0% in 2023.
  • Traws Pharma's Change in Receivables stood at -$1000.0 in 2021, then changed by 0.0% to -$1000.0 in 2022, then surged by 200.0% to $1000.0 in 2023, then plummeted by 35700.0% to -$356000.0 in 2024, then surged by 287.64% to $668000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Change in Receivables are $668000.0 (Q3 2025), -$331000.0 (Q2 2025), and -$111000.0 (Q1 2025).